ESSA Historical Income Statement

EPIX Stock

USD 1.75 0.04 2.23%

Historical analysis of ESSA Pharma income statement accounts such as Selling General Administrative of 7.5 M or Total Revenue of 0.0 can show how well ESSA Pharma performed in making a profits. Evaluating ESSA Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ESSA Pharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ESSA Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ESSA Pharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

About ESSA Income Statement Analysis

ESSA Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ESSA Pharma shareholders. The income statement also shows ESSA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ESSA Pharma Income Statement Chart

At this time, ESSA Pharma's Research Development is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 143.1 K in 2024, whereas Interest Expense is likely to drop 5,935 in 2024.

Research Development Effect Of Accounting Charges Extraordinary Items Net Income

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in ESSA Pharma financial statement analysis. It represents the amount of money remaining after all of ESSA Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from ESSA Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.At this time, ESSA Pharma's Research Development is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 143.1 K in 2024, whereas Interest Expense is likely to drop 5,935 in 2024.

ESSA Pharma income statement Correlations

	Interest Expense	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Depreciation And Amortization	Ebitda	Interest Income	Tax Provision	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Interest Expense		-0.02	0.23	-0.1	0.08	0.15	0.05	-0.22	-0.14	-0.1	0.15	0.2	0.15	0.17	-0.19	0.07	-0.16	0.08	-0.4	-0.41	0.27
Selling General Administrative	-0.02		-0.85	0.98	-0.96	-0.95	-0.95	0.89	0.9	0.98	-0.95	0.32	-0.95	-0.51	0.94	-0.95	0.32	-0.72	0.58	0.86	-0.23
Gross Profit	0.23	-0.85		-0.82	0.83	0.85	0.82	-0.82	-0.89	-0.82	0.85	-0.21	0.85	0.58	-0.77	0.82	-0.29	0.76	-0.66	-0.75	0.34
Other Operating Expenses	-0.1	0.98	-0.82		-0.98	-0.95	-0.96	0.93	0.85	1.0	-0.95	0.39	-0.95	-0.37	0.95	-0.96	0.34	-0.62	0.62	0.86	-0.23
Operating Income	0.08	-0.96	0.83	-0.98		0.98	0.99	-0.96	-0.87	-0.98	0.98	-0.43	0.98	0.36	-0.92	0.99	-0.37	0.62	-0.65	-0.83	0.32
Net Income From Continuing Ops	0.15	-0.95	0.85	-0.95	0.98		0.99	-0.94	-0.88	-0.95	1.0	-0.25	1.0	0.47	-0.89	0.99	-0.24	0.72	-0.59	-0.83	0.3
Ebit	0.05	-0.95	0.82	-0.96	0.99	0.99		-0.94	-0.85	-0.96	0.99	-0.36	0.99	0.39	-0.89	1.0	-0.29	0.65	-0.56	-0.8	0.28
Research Development	-0.22	0.89	-0.82	0.93	-0.96	-0.94	-0.94		0.88	0.93	-0.94	0.51	-0.94	-0.29	0.89	-0.94	0.48	-0.56	0.79	0.84	-0.53
Cost Of Revenue	-0.14	0.9	-0.89	0.85	-0.87	-0.88	-0.85	0.88		0.85	-0.88	0.36	-0.88	-0.5	0.82	-0.85	0.52	-0.69	0.78	0.8	-0.53
Total Operating Expenses	-0.1	0.98	-0.82	1.0	-0.98	-0.95	-0.96	0.93	0.85		-0.95	0.39	-0.95	-0.37	0.95	-0.96	0.34	-0.62	0.62	0.86	-0.23
Income Before Tax	0.15	-0.95	0.85	-0.95	0.98	1.0	0.99	-0.94	-0.88	-0.95		-0.25	1.0	0.48	-0.89	0.99	-0.24	0.73	-0.59	-0.83	0.3
Total Other Income Expense Net	0.2	0.32	-0.21	0.39	-0.43	-0.25	-0.36	0.51	0.36	0.39	-0.25		-0.25	0.39	0.38	-0.35	0.8	0.22	0.61	0.27	-0.52
Net Income	0.15	-0.95	0.85	-0.95	0.98	1.0	0.99	-0.94	-0.88	-0.95	1.0	-0.25		0.47	-0.89	0.99	-0.24	0.72	-0.6	-0.83	0.3
Income Tax Expense	0.17	-0.51	0.58	-0.37	0.36	0.47	0.39	-0.29	-0.5	-0.37	0.48	0.39	0.47		-0.49	0.41	0.12	0.86	-0.16	-0.57	0.01
Depreciation And Amortization	-0.19	0.94	-0.77	0.95	-0.92	-0.89	-0.89	0.89	0.82	0.95	-0.89	0.38	-0.89	-0.49		-0.89	0.41	-0.66	0.68	0.96	-0.27
Ebitda	0.07	-0.95	0.82	-0.96	0.99	0.99	1.0	-0.94	-0.85	-0.96	0.99	-0.35	0.99	0.41	-0.89		-0.28	0.65	-0.57	-0.81	0.28
Interest Income	-0.16	0.32	-0.29	0.34	-0.37	-0.24	-0.29	0.48	0.52	0.34	-0.24	0.8	-0.24	0.12	0.41	-0.28		0.14	0.75	0.44	-0.62
Tax Provision	0.08	-0.72	0.76	-0.62	0.62	0.72	0.65	-0.56	-0.69	-0.62	0.73	0.22	0.72	0.86	-0.66	0.65	0.14		-0.35	-0.66	0.15
Net Interest Income	-0.4	0.58	-0.66	0.62	-0.65	-0.59	-0.56	0.79	0.78	0.62	-0.59	0.61	-0.6	-0.16	0.68	-0.57	0.75	-0.35		0.72	-0.76
Reconciled Depreciation	-0.41	0.86	-0.75	0.86	-0.83	-0.83	-0.8	0.84	0.8	0.86	-0.83	0.27	-0.83	-0.57	0.96	-0.81	0.44	-0.66	0.72		-0.33
Selling And Marketing Expenses	0.27	-0.23	0.34	-0.23	0.32	0.3	0.28	-0.53	-0.53	-0.23	0.3	-0.52	0.3	0.01	-0.27	0.28	-0.62	0.15	-0.76	-0.33

Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	618K	22.2K	14K	6.9K	6.2K	5.9K
Selling General Administrative	11.4M	12.8M	12.5M	10.8M	12.4M	7.5M
Other Operating Expenses	23.5M	37.1M	37.0M	32.1M	37.0M	19.3M
Operating Income	(23.1M)	(36.9M)	(35.3M)	(32.1M)	(28.9M)	(27.5M)
Net Income From Continuing Ops	(23.4M)	(36.8M)	(35.1M)	(26.6M)	(23.9M)	(25.1M)
Ebit	(23.1M)	(36.8M)	(35.2M)	(26.6M)	(23.9M)	(25.1M)
Research Development	12.1M	24.3M	24.4M	21.3M	24.5M	25.7M
Cost Of Revenue	110.3K	109.5K	121.8K	118.5K	136.3K	143.1K
Total Operating Expenses	23.5M	37.1M	37.0M	32.1M	37.0M	19.3M
Income Before Tax	(23.7M)	(36.8M)	(35.2M)	(26.6M)	(23.9M)	(25.1M)
Total Other Income Expense Net	(214.1K)	303.8K	1.7M	5.6M	6.4M	6.7M
Net Income Applicable To Common Shares	(12.8M)	(23.4M)	(36.8M)	(35.1M)	(31.6M)	(30.0M)
Net Income	(23.4M)	(36.8M)	(35.1M)	(26.6M)	(23.9M)	(25.1M)
Income Tax Expense	(289K)	(34.3K)	(112K)	1.6K	1.4K	1.4K
Depreciation And Amortization	110.3K	109.5K	121.8K	118.5K	136.3K	75.6K
Ebitda	(23.0M)	(36.7M)	(35.1M)	(26.5M)	(23.8M)	(25.0M)
Interest Income	559.7K	235.0K	1.7M	5.6M	6.4M	6.7M
Tax Provision	(288.6K)	(34.3K)	(111.8K)	1.6K	1.4K	1.4K
Net Interest Income	(58.4K)	212.8K	1.7M	5.5M	6.4M	6.7M
Reconciled Depreciation	110.3K	109.5K	121.8K	118.5K	136.3K	87.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ESSA Historical Income Statement

About ESSA Income Statement Analysis

ESSA Pharma Income Statement Chart

Net Income

ESSA Pharma income statement Correlations

ESSA Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ESSA Pharma income statement Accounts

Also Currently Popular

Additional Tools for ESSA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Discontinued Operations	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Cost Of Revenue	Non Recurring
Total Operating Expenses	Effect Of Accounting Charges
Income Before Tax	Extraordinary Items
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Minority Interest	Other Items
Depreciation And Amortization	Ebitda
Interest Income	Preferred Stock And Other Adjustments
Non Operating Income Net Other	Tax Provision
Net Interest Income	Reconciled Depreciation
Selling And Marketing Expenses

Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Ebit	+ 0.99	Operating Income

Total Operating Expenses	- 0.98	Operating Income
Operating Income	- 0.98	Other Operating Expenses
Ebitda	- 0.96	Total Operating Expenses
Total Operating Expenses	- 0.96	Ebit
Research Development	- 0.96	Operating Income
Ebitda	- 0.96	Other Operating Expenses